Lakewood-Amedex's Nu-3 Advances Toward Phase 2 Clinical Trials
Lakewood-Amedex Biotherapeutics has announced advancements for its lead compound, Nu-3, now progressing toward a Phase 2 clinical trial targeting mildly infected diabetic foot ulcers. The positive data regarding its formulation and manufacturing processes could bolster investor confidence in its potential market impact amid rising concerns over antimicrobial resistance.
View signal analysis